India, June 14 -- Hyderabad-based Bharat Biotech has partnered with GSK-a British multinational pharmaceutical and biotechnology company-for the ongoing development and potential use of the Shigella vaccine candidate, altSonflex1-2-3, the companies announced in a joint statement on Thursday.

The partnership will mark a critical step in the advancement of this promising vaccine, targeting Shigellosis-a severe form of bacterial diarrhoea that disproportionately affects children under five in low- and middle-income countries. India is also impacted.

A 2021 study published in the Indian Journal of Medical Biology- Antimicrobial Resistant Shigella in North India Since the Turn of the 21st Century - talks about how the ubiquitous presence and...